<DOC>
	<DOCNO>NCT00869700</DOCNO>
	<brief_summary>Despite clinical significance potential interaction antimalarial antiretrovirals , drug interaction study publish urgent need address gap current knowledge . The aim study investigate pharmacokinetics ( PK ) antimalarial combination artemether/lumefantrine ( AL ) combination antiretroviral therapy ( cART ) include lopinavir/ritonavir ( LPV/r ) HIV-infected adult .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between Antimalarial Combination Artemether/Lumefantrine Combination Antiretroviral Therapy Including Lopinavir/Ritonavir HIV-infected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Informed give ample time opportunity think participation willing able comprehend comply trial requirement . The participant give write informed consent participate study abide study restriction . Male female subject 18 year age old . HIVinfected document positive HIVantibody test confirm Western blot . Body weight 35kg body mass index ( BMI ) range 18.5 30kg/m2 inclusive ( See Appendix 15.2 ) . Karnofsky score 70 ( See Appendix 15.5 ) . CD4 count ≥ 200 cells/mm3 Patients LPV/rbased cART stable dos without significant toxicity least 6 week screen . Patients diagnose malaria Contraindications artemether/lumefantrine : Hypersensitivity artemether , lumefantrine excipients Coartem® . Pregnant ( confirm HCG test perform screen ) breastfeed female . Patients family history congenital prolongation QTc interval sudden death clinical condition know prolong QTc interval patient history symptomatic cardiac arrhythmia , clinically relevant bradycardia severe cardiac disease . Patients known disturbance electrolyte balance e.g . hypokalaemia hypomagnesaemia . Patients take drug metabolise cytochrome enzyme CYP2D6 ( e.g . flecainide , metoprolol , imipramine , amitriptyline , clomipramine ) CYP3A4 . Patients take drug know prolong QTc interval antiarrhythmic class IA III , neuroleptic , antidepressive agent , certain antibiotic include agent follow class : macrolides , fluoroquinolones , imidazole , triazole antifungal agent , certain nonsedating antihistaminics ( terfenadine , astemizole ) , cisapride . Haemoglobin 8.5g/dL female 9.5g/dL male subject . Relevant history current condition ( ) might interfere drug absorption , distribution , metabolism excretion . Current smoker , subject stop smoke less 3 month prior date screening . History , current , substance abuse problem positive urine screen drug abuse . History alcohol abuse . The subject consume alcohol , grapefruit caffeinecontaining product ( ie tea , coffee , cola , chocolate ) within 24 hour dose AL PK profile . The subject participate strenuous exercise within 24 hour AL dose . Severely ill suffer serious underlying disease ( particularly cardiac , hepatic renal disease ) opinion Investigator would make participant unsuitable study term safety study analysis . The volunteer participate another study investigational product within 8 week first administration current investigational product , least 5 x t½ elimination lapse , whichever great . Subjects , opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Malaria</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>